
Emergent BioSolutions Inc.: updates and filings
Price
$5.61
November 17, 2026Market cap $290M
What Ploutos Investor adds for Emergent BioSolutions
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 2, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Other material eventsForm8-K
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 16, 2026Officer or director changeForm8-K
- Sep 14, 2026Regulation FD disclosureForm8-K
- Sep 1, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, restructuring costs, officer or director change, Regulation FD disclosureForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 28, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 29, 2026Material agreement entered, Regulation FD disclosureForm8-K
- May 1, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Shares registered for employeesFormS-8
- Apr 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 30, 2026Shareholder voteForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 17, 2026Material agreement entered, material agreement ended, unregistered sale of shares, Regulation FD disclosureForm8-K
- Apr 16, 2026Additional annual meeting materialFormDEFA14A
- Apr 16, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 8-K | Other material events | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 16, 2026 | 8-K | Officer or director change | Document |
| Sep 14, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 1, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, restructuring costs, officer or director change, Regulation FD disclosure | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 28, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 29, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| May 1, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | S-8 | Shares registered for employees | Document |
| Apr 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 30, 2026 | 8-K | Shareholder vote | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 17, 2026 | 8-K | Material agreement entered, material agreement ended, unregistered sale of shares, Regulation FD disclosure | Document |
| Apr 16, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 16, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 14, 2006.
The full analysis
What do Emergent BioSolutions's filings show?
The filings are where every one of Emergent BioSolutions's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.